Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: No
- Resource Type
- Source
- Multiple Sclerosis Journal. 28:1175-1177
- Subject
Neurology Antibodies, Monoclonal Humans Antineoplastic Agents Neurology (clinical) Antigens, CD20 Rituximab - Language
- ISSN
- 1477-0970
1352-4585